As Table 7 shows, the mutation rate of KRAS was higher in men than women (16.06% vs. 0.56%, P< 0.001), higher in older patients than younger patients (11.41% vs. 6.94%, P = 0.028), higher in current or former smokers than non-smokers (16.81% vs. 4.55%, P< 0.001), higher in abnormal serum tumor markers than normal serum tumor markers (10.78% vs. 4.92%, P = 0.017), and higher in advanced stage than early stage (12.45% vs. 5.04%, P< 0.001). The gene discussed is KRAS; the disease is neoplasm.